Every 10-Q that Evolus, Inc. (EOLS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EOLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EOLS filings page.
Evolus, Inc., a performance beauty company focused on cash‑pay aesthetics, reported higher Q2 2026 net revenues of $84,084 thousand, up from $69,387 thousand a year earlier. For the first half of 2026, net revenues were $157,221 thousand with gross profit of $106,077 thousand.
The business remains unprofitable but losses narrowed. Q2 net loss was $8,052 thousand versus $17,142 thousand in 2025, and six‑month net loss was $18,726 thousand versus $36,034 thousand. Cash used in operating activities was $13,539 thousand, compared with $40,423 thousand, and results include a $1,949 thousand tariff‑refund receivable that reduced costs.
As of June 30, 2026, Evolus held $45,170 thousand in cash and cash equivalents, a stockholders’ deficit of $30,903 thousand, and long‑term debt of $156,744 thousand, mainly New Pharmakon Term Loans and a $10,000 thousand asset‑based revolver draw. Management believes existing cash, operations and committed credit facilities will fund operations for at least the next twelve months.
Evolus, Inc. reported first-quarter 2026 results showing modest revenue growth but continuing losses. Total net revenues were $73.1 million, up from $68.5 million a year earlier, driven mainly by Jeuveau and Evolysse product sales. The company posted a net loss of $10.7 million, an improvement from a $18.9 million loss in the prior-year quarter, with loss per share narrowing to $0.16 from $0.30. Cash and cash equivalents were $49.8 million and operating activities used $10.0 million of cash. Evolus’ balance sheet shows total assets of $220.6 million, long-term debt of $156.4 million and a stockholders’ deficit of $28.8 million. Management believes its cash, expected operating cash flows and access to a $30 million asset-based revolving credit facility plus up to $250 million of Pharmakon term loans are sufficient to fund operations for at least the next 12 months. The company highlights ongoing risks including reliance on Jeuveau and Evolysse, significant competition in aesthetics, regulatory dependencies on partners Daewoong and Symatese, required milestone and royalty payments, and a history of accumulated deficits.
Evolus, Inc. reported Q3 2025 results with total net revenues of $68,967, up from $61,085 a year ago. Gross profit was $45,841, but operating expenses of $57,341 (including $1,443 in restructuring costs) led to a loss from operations of $11,500 and a net loss of $15,737, or $0.24 per share.
Cash and cash equivalents were $43,523 at quarter end, with net cash used in operating activities of $55,092 year-to-date. Long‑term debt on the balance sheet was $145,780, reflecting the May 2025 Amended and Restated Loan Agreement that provides up to $250,000 in senior secured term loans, including an initial $150,000 funded. Stockholders’ equity was a deficit of $28,760. The company launched Evolysse Form and Smooth in the U.S. in April 2025 and continues to commercialize Jeuveau across multiple markets. Shares outstanding were 64,819,784 as of October 31, 2025.